Cellectis (CLLS) Interest Expenses (2015 - 2026)
Cellectis' (CLLS) quarterly Interest Expenses came in at -$4.4 million in Q1 2026, up 56.63% year-on-year from -$2.8 million in Q1 2025, and down 104.9% quarter-over-quarter from $90.7 million in Q4 2025.
Cellectis (CLLS) Interest Expenses (2015 - 2026) Analysis & Trends
Cellectis' Interest Expenses history runs 12 years deep, the most recent figure standing at -$4.4 million for Q1 2026.
- On a quarterly basis, Interest Expenses rose 56.63% year-over-year to -$4.4 million in Q1 2026; TTM through Mar 2026 was $55.7 million, a 1555.4% increase from a year earlier, with the FY2025 full-year figure at $51.1 million, up 136.25% from the prior year.
- Interest Expenses eased to -$4.4 million in Q1 2026 per CLLS's latest filing, from $90.7 million in the prior quarter.
- Across five years, Interest Expenses topped out at $90.7 million in Q4 2025 and bottomed at -$19.7 million in Q2 2025.
- The 5-year median for Interest Expenses is -$1.7 million (2022), against an average of $10.4 million.
- Across the five-year window, Interest Expenses sank 1134.55% in 2022 and jumped 2221.78% in 2023, its largest moves.
- Year by year, Interest Expenses stood at $22.0 million in 2022, then surged by 190.28% to $63.7 million in 2023, then slipped by 28.35% to $45.7 million in 2024, then surged by 98.68% to $90.7 million in 2025, then plunged by 104.9% to -$4.4 million in 2026.
- Per Business Quant, the three latest CLLS Interest Expenses figures stand at -$4.4 million (Q1 2026), $90.7 million (Q4 2025), and -$10.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | -4.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.44 Mn |
| Mar 31, 2026 | -4.44 Mn |
| Dec 31, 2025 | 90.72 Mn |
| Dec 31, 2025 | 90.72 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Dec 31, 2024 | 45.66 Mn |
| Dec 31, 2024 | 45.66 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Jun 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -16.65 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Dec 31, 2023 | 63.73 Mn |
| Dec 31, 2023 | 63.73 Mn |